Outcome Measures in Relapsing-Remitting Multiple Sclerosis: Capturing Disability and Disease Progression in Clinical Trials

Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disease that manifests as acute relapses and progressive disability. As a primary endpoint for clinical trials in MS, disability is difficult to both characterize and measure. Furthermore, the recovery from relapses and the rate of disability vary considerably among patients. Given these challenges, investigators have developed and studied the performance of various outcome measures and surrogate endpoints in MS clinical trials. This review defines the outcome measures and surrogate endpoints used to date in MS clinical trials and presents challenges in the design of both adult and pediatric trials.

• Publication year

  2014

• Venue

  Multiple Sclerosis International

• Publication date

  2014-05-04

• Fields of study

  Medicine

• Identifiers
  DOI 10.1155/2014/262350PMID 24883205PMCID 4026972
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis

  2014cited by this paper
• Magnetic resonance imaging correlates of physical disability in relapse onset multiple sclerosis of long disease duration

  2014cited by this paper
• The relationship between total and regional corpus callosum atrophy, cognitive impairment and fatigue in multiple sclerosis patients

  2014cited by this paper
• Relevance of hypointense brain MRI lesions for long-term worsening of clinical disability in relapsing multiple sclerosis

  2014cited by this paper
• Evaluation of inner retinal layers in patients with multiple sclerosis or neuromyelitis optica using optical coherence tomography.

  2013cited by this paper
• Time to first relapse as an endpoint in multiple sclerosis clinical trials

  2013cited by this paper
• Loss of retinal nerve fibre layer axons indicates white but not grey matter damage in early multiple sclerosis

  2013cited by this paper
• International Pediatric MS Study Group Clinical Trials Summit

  2013influential reference
• Brain atrophy and lesion load predict long term disability in multiple sclerosis

  2013cited by this paper
• Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage

  2013cited by this paper
• Clinical and MRI activity as determinants of sample size for pediatric multiple sclerosis trials

  2013cited by this paper
• Optic neuritis interferes with optical coherence tomography and magnetic resonance imaging correlations

  2013cited by this paper
• 2010 McDonald criteria for diagnosing pediatric multiple sclerosis

  2012cited by this paper
• Biomarkers and surrogate endpoints in clinical trials

  2012influential reference
• Application of the 2010 McDonald criteria for the diagnosis of multiple sclerosis in a Spanish cohort of patients with clinically isolated syndromes

  2012cited by this paper
• Progressive degeneration of the retinal nerve fiber layer in patients with multiple sclerosis.

  2012cited by this paper
• Ethical challenges in paediatric clinical trials in multiple sclerosis

  2012cited by this paper
• Revisiting The Multiple Sclerosis Functional Composite: proceedings from the National Multiple Sclerosis Society (NMSS) Task Force on Clinical Disability Measures

  2012influential reference
• Consensus statement: evaluation of new and existing therapeutics for pediatric multiple sclerosis

  2012cited by this paper
• Randomized trial of oral teriflunomide for relapsing multiple sclerosis.

  2011cited by this paper
• MRI correlates of cognitive impairment in childhood-onset multiple sclerosis.

  2011cited by this paper
• The Impact of Utilizing Different Optical Coherence Tomography Devices for Clinical Purposes and in Multiple Sclerosis Trials

  2011cited by this paper
• Magnetic resonance active lesions as individual-level surrogate for relapses in multiple sclerosis

  2011cited by this paper
• Rituximab add-on therapy for breakthrough relapsing multiple sclerosis

  2010cited by this paper
• Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes

  2010cited by this paper
• A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.

  2010cited by this paper
• Assessing changes in relapse rates in multiple sclerosis

  2010cited by this paper
• Therapeutic Advances in Neurological Disorders Angelo Ghezzi Therapeutic strategies in childhood multiple sclerosis

  2010cited by this paper
• Cognitive and psychosocial features in childhood and juvenile MS

  2010cited by this paper
• Longitudinal study of vision and retinal nerve fiber layer thickness in multiple sclerosis

  2010cited by this paper
• Investigative Ophthalmology and Visual Science

  2010cited by this paper
• Gray matter atrophy correlates with MS disability progression measured with MSFC but not EDSS.

  2009cited by this paper
• Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis.

  2009cited by this paper
• Difference in disease burden and activity in pediatric patients on brain magnetic resonance imaging at time of multiple sclerosis onset vs adults.

  2009cited by this paper
• Sample sizes for brain atrophy outcomes in trials for secondary progressive multiple sclerosis

  2009cited by this paper
• Gray matter atrophy correlates with MS disability progression measured with MSFC but not EDSS.

  2009cited by this paper
• Macular volume determined by optical coherence tomography as a measure of neuronal loss in multiple sclerosis.

  2009cited by this paper
• Pediatric central nervous system inflammatory demyelination: acute disseminated encephalomyelitis, clinically isolated syndromes, neuromyelitis optica, and multiple sclerosis

  2009cited by this paper
• Efficacy of treatment of MS with IFN -1b or glatiramer acetate by monthly brain MRI in the BECOME study

  2009cited by this paper
• Effect of statins on clinical and molecular responses to intramuscular interferon beta-1a

  2009cited by this paper
• Imaging outcomes for neuroprotection and repair in multiple sclerosis trials

  2009cited by this paper
• Assessing disability progression with the Multiple Sclerosis Functional Composite

  2009cited by this paper
• Pediatric multiple sclerosis

  2009cited by this paper
• Gadolinium-enhancing or active T2 magnetic resonance imaging lesions in multiple sclerosis clinical trials?

  2009cited by this paper
• Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: A meta‐analytic approach

  2009cited by this paper
• Disability as an outcome in MS clinical trials

  2008cited by this paper
• Historical and Clinical Perspectives of the Expanded Disability Status Scale

  2008cited by this paper
• Optical coherence tomography: a window into the mechanisms of multiple sclerosis

  2008cited by this paper
• Cognitive and psychosocial features of childhood and juvenile MS

  2008cited by this paper
• Natalizumab reduces visual loss in patients with relapsing multiple sclerosis

  2007influential reference
• Axonal loss is progressive and partly dissociated from lesion load in early multiple sclerosis

  2007cited by this paper
• MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS

  2007cited by this paper
• IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event.

  2006cited by this paper
• Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes

  2006cited by this paper
• Relation of visual function to retinal nerve fiber layer thickness in multiple sclerosis.

  2006cited by this paper
• IM interferon β-1a delays definite multiple sclerosis 5 years after a first demyelinating event

  2006cited by this paper
• Left insular stroke is associated with adverse cardiac outcome

  2006cited by this paper
• The measurement and clinical relevance of brain atrophy in multiple sclerosis.

  2006cited by this paper
• Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes

  2006cited by this paper
• A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.

  2006cited by this paper
• Multiple sclerosis trial designs for the 21st century: Building on recent lessons

  2005cited by this paper
• Low-contrast letter acuity testing captures visual dysfunction in patients with multiple sclerosis

  2005cited by this paper
• Retinal nerve fiber layer axonal loss and visual dysfunction in optic neuritis

  2005cited by this paper
• MRI metrics as surrogate endpoints for EDSS progression in SPMS patients treated with IFN β-1b

  2003cited by this paper
• Contrast letter acuity as a visual component for the Multiple Sclerosis Functional Composite

  2003cited by this paper
• A LONGITUDINAL STUDY OF ABNORMALITIES ON MRI AND DISABILITY FROM MULTIPLE SCLEROSIS

  2002cited by this paper
• A longitudinal study of abnormalities on MRI and disability from multiple sclerosis.

  2002cited by this paper
• The clinico‐radiological paradox in multiple sclerosis revisited

  2002cited by this paper
• Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes".

  2002cited by this paper
• Clinical Outcome Measures for Research in Multiple Sclerosis

  2001cited by this paper
• Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study.

  2001cited by this paper
• Glatiramer acetate reduces the proportion of new MS lesions evolving into “black holes”

  2001cited by this paper
• Use of the Multiple Sclerosis Functional Composite to predict disability in relapsing MS

  2001cited by this paper
• Clinical trials of multiple sclerosis monitored with enhanced MRI: new sample size calculations based on large data sets

  2001cited by this paper
• Clinical significance of the multiple sclerosis functional composite: relationship to patient-reported quality of life.

  2000cited by this paper
• Neurological disability correlates with spinal cord axonal loss and reduced N‐acetyl aspartate in chronic multiple sclerosis patients

  2000cited by this paper
• New low-contrast vision charts: reliability and test characteristics in patients with multiple sclerosis

  2000cited by this paper
• Development of hypointense lesions on T1-weighted spin-echo magnetic resonance images in multiple sclerosis: relation to inflammatory activity.

  1999cited by this paper
• Correlation between morphological and functional retinal impairment in multiple sclerosis patients.

  1999cited by this paper
• The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis.

  1999cited by this paper
• Development of a multiple sclerosis functional composite as a clinical trial outcome measure.

  1999cited by this paper
• Axonal loss in multiple sclerosis lesions: Magnetic resonance imaging insights into substrates of disability

  1999cited by this paper
• Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group.

  1999cited by this paper
• T1 hypointense lesion load in secondary progressive multiple sclerosis: a comparison of pre versus post contrast loads and of manual versus semi automated threshold techniques for lesion segmentation

  1998cited by this paper
• Recommendations from the national multiple sclerosis society clinical outcomes assessment task force

  1997cited by this paper
• Surrogate End Points in Clinical Trials: Are We Being Misled?

  1996cited by this paper
• Accumulation of hypointense lesions ("black holes") on T1 spin-echo MRI correlates with disease progression in multiple sclerosis

  1996cited by this paper
• Correlating MRI and clinical disease activity in multiple sclerosis

  1995cited by this paper
• Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis

  1995cited by this paper
• Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group.

  1995cited by this paper
• Inter‐ and intrarater scoring agreement using grades 1.0 to 3.5 of the Kurtzke Expanded Disability Status Scale (EDSS)

  1992cited by this paper
• The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course.

  1989cited by this paper

• Improved Assessment of Juxtacortical Lesions in Multiple Sclerosis Using Highly-accelerated High-resolution Double Inversion Recovery MR Imaging with Deep Learning-based Reconstruction

  2025cites this paper
• Analyzing recurrent events in multiple sclerosis: a review of statistical models with application to the MSOAC database

  2025cites this paper
• Lymphocyte Dynamics and the Emergence of Secondary Autoimmunity Following Immune Reconstitution Therapies in Multiple Sclerosis

  2025cites this paper
• Disability, health-related quality of life, and self-concept change in people with multiple sclerosis: A moderated mediation.

  2024cites this paper
• Cost and Quality of Life of Disability Progression in Multiple Sclerosis Beyond EDSS: Impact of Cognition, Fatigue, and Limb Impairment

  2024cites this paper
• The effect of alemtuzumab on neurodegeneration in relapsing-remitting multiple sclerosis: A five-year prospective mono-center study.

  2024cites this paper
• Real-world annualized relapse rates from contemporary multiple sclerosis clinics in the UK: a retrospective multicentre cohort study

  2023cites this paper
• Study to Compare the Efficacy and Cost-Effectiveness of Various Disease Modifying Drugs in the Management of Multiple Sclerosis in India- An Observational Study

  2023cites this paper
• The socioeconomic impact of disability progression in multiple sclerosis: A retrospective cohort study of the German NeuroTransData (NTD) registry

  2023cites this paper
• Thin-slice Two-dimensional T2-weighted Imaging with Deep Learning-based Reconstruction: Improved Lesion Detection in the Brain of Patients with Multiple Sclerosis

  2023cites this paper
• Diffusion tensor imaging changes of the cortico-thalamic-striatal tracts correlate with fatigue and disability in people with relapsing-remitting MS.

  2023cites this paper
• Comparative efficacy and safety of disease-modifying therapies in patients with relapsing multiple sclerosis: A systematic review and network meta-analysis.

  2022cites this paper
• Angle-angle diagrams in the assessment of locomotion in persons with multiple sclerosis: A preliminary study

  2022cites this paper
• Brain grey matter perfusion in primary progressive multiple sclerosis: Mild decrease over years and regional associations with cognition and hand function

  2022cites this paper
• Genetic Variation in WNT9B Increases Relapse Hazard in Multiple Sclerosis

  2021cites this paper
• Quality of life measures in pediatric multiple sclerosis: a systematic review and meta‐analysis

  2021cites this paper
• A non-parametric propensity score for estimating the effect of interferon-beta or glatiramer acetate on long-term outcomes of multiple sclerosis.

  2021cites this paper
• Evaluation of an interactive web-based programme on relapse management for people with multiple sclerosis (POWER@MS2): study protocol for a process evaluation accompanying a randomised controlled trial

  2021cites this paper
• Predicting Long-term Disability in Multiple Sclerosis: A Narrative Review of Current Evidence and Future Directions.

  2021cites this paper
• Laboratory Biomarkers of Multiple Sclerosis (MS).

  2021cites this paper
• Immunotherapy – A Novel Facet of Modern Therapeutics

  2021cites this paper
• Safety and efficacy of mycophenolate mofetil in treating neuromyelitis optica spectrum disorders: a protocol for systematic review and meta-analysis

  2020cites this paper
• A literature review of cost-of-illness studies on the economic burden of multiple sclerosis.

  2020cites this paper
• Safety and efficacy of plasma exchange for the treatment of optic neuritis in neuromyelitis optica spectrum disorders

  2020cites this paper
• Nine Hole Peg Test asymmetry in refining upper limb assessment in multiple sclerosis.

  2020cites this paper
• Functioning Profiles of Young People with MS in Inpatient Rehabilitation: Data from the National Rehabilitation Reporting System in Canada.

  2020cites this paper
• Efficacy outcomes reported in trials of multiple sclerosis: A systematic scoping review.

  2020cites this paper
• Outcome measures for disease-modifying therapies in relapsing multiple sclerosis randomized clinical trials: a scoping review protocol.

  2020influential citation
• Evolution of Cortical and White Matter Lesion Load in Early-Stage Multiple Sclerosis: Correlation With Neuroaxonal Damage and Clinical Changes

  2020cites this paper
• Predictors of Health Utility in Relapsing–Remitting and Secondary-Progressive Multiple Sclerosis: Implications for Future Economic Models of Disease-Modifying Therapies

  2020cites this paper
• Clinical outcome measures in multiple sclerosis: A review.

  2020cites this paper
• Systematic review and meta-analysis of the development of multiple sclerosis in clinically isolated syndrome

  2020cites this paper
• Immunotherapy in Neurodegenerative Disorders

  2020cites this paper
• A pharmacogenetic study implicates NINJ2 in the response to Interferon-β in multiple sclerosis

  2020cites this paper
• Gait abnormalities in minimally disabled people with Multiple Sclerosis: A 3D-motion analysis study.

  2019cites this paper
• (2019). Systematic review and network meta-analysis comparing ocrelizumab with other treatments for relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders , 29 , 55-61.

  2019cites this paper
• Long noncoding RNAs APOA1-AS, IFNG-AS1, RMRP and their related biomolecules in Egyptian patients with relapsing-remitting multiple sclerosis: Relation to disease activity and patient disability

  2019influential citation
• Enduring Clinical Value of Copaxone® (Glatiramer Acetate) in Multiple Sclerosis after 20 Years of Use

  2019cites this paper
• Impact of informative censoring on the treatment effect estimate of disability worsening in multiple sclerosis clinical trials.

  2019cites this paper
• Therapeutic Apheresis in Acute Relapsing Multiple Sclerosis: Current Evidence and Unmet Needs—A Systematic Review

  2019cites this paper
• Systematic review and network meta-analysis comparing ocrelizumab with other treatments for relapsing multiple sclerosis.

  2019cites this paper
• Standardizing Magnetic Resonance Imaging Protocols, Requisitions, and Reports in Multiple Sclerosis: An Update for Radiologist Based on 2017 Magnetic Resonance Imaging in Multiple Sclerosis and 2018 Consortium of Multiple Sclerosis Centers Consensus Guidelines

  2019cites this paper
• Efficacy and tolerability of mitoxantrone for neuromyelitis optica spectrum disorder: A systematic review.

  2019cites this paper
• 46 – Multiple Sclerosis

  2018cites this paper
• Disability Outcome Measures in Phase III Clinical Trials in Multiple Sclerosis

  2018influential citation
• No evidence of disease activity in patients receiving fingolimod at private or academic centers in clinical practice: a retrospective analysis of the multiple sclerosis, clinical, and magnetic resonance imaging outcomes in the USA (MS-MRIUS) study

  2018cites this paper
• A Systematic Review of Discrete-Choice Experiments and Conjoint Analysis Studies in People with Multiple Sclerosis

  2018cites this paper
• Deimination in Multiple Sclerosis: The Bad, the Good, and the Ugly

  2017cites this paper
• Exposure–disease response analysis of natalizumab in subjects with multiple sclerosis

  2017cites this paper
• Vitamin D and disability in relapsing–remitting multiple sclerosis in patients with a Mexican background

  2017cites this paper
• A pharmacogenetic signature of high response to Copaxone in late-phase clinical-trial cohorts of multiple sclerosis

  2017cites this paper
• No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE study

  2017cites this paper
• Clinical characteristics of late-onset neuromyelitis optica spectrum disorder: A multicenter retrospective study in Korea

  2017cites this paper
• Identifying Relapses in Multiple Sclerosis Patients through Administrative Data: A Validation Study in the Lazio Region, Italy

  2017cites this paper
• Time course of glatiramer acetate efficacy in patients with RRMS in the GALA study

  2017cites this paper
• Longitudinal Models for Quantifying Disease and Therapeutic Response in Multiple Sclerosis

  2017cites this paper
• Synthetic MRI in the Detection of Multiple Sclerosis Plaques

  2017cites this paper
• Multiple sclerosis in the real world: A systematic review of fingolimod as a case study.

  2017cites this paper
• Impact of daclizumab versus interferon beta-1a on patient-reported outcomes in relapsing-remitting multiple sclerosis.

  2017cites this paper
• Central Atrophy Early in Multiple Sclerosis: Third Ventricle Volumetry versus Planimetry

  2017cites this paper
• Factors associated with adherence to disease modifying therapy in multiple sclerosis: An observational survey from a referral center in Lithuania.

  2017cites this paper
• Use Case I: Imaging Biomarkers in Neurological Disease. Focus on Multiple Sclerosis

  2017cites this paper
• Clinical Research in Neurology

  2017cites this paper
• Efficacy of daclizumab beta versus intramuscular interferon beta-1a on disability progression across patient demographic and disease activity subgroups in DECIDE

  2017cites this paper
• CHARACTERIZATION OF GAIT DEFICITS IN A MOUSE MODEL OF MULTIPLE SCLEROSIS

  2017cites this paper
• Study design of PANGAEA 2.0, a non-interventional study on RRMS patients to be switched to fingolimod

  2016cites this paper
• Currently approved and emerging oral therapies in multiple sclerosis: An update for the ophthalmologist.

  2016cites this paper
• Fingolimod for relapsing-remitting multiple sclerosis.

  2016cites this paper
• How to assess response to immune therapy

  2016cites this paper
• Introduction to Organ Fabrication

  2016cites this paper
• Multimodal assessment of neurodegenerative diseases

  2016influential citation
• Optic neuritis in children

  2016cites this paper
• Long-term adherence of patients with relapsing-remitting multiple sclerosis to subcutaneous self-injections of interferon β-1a using an electronic device: the RIVER study

  2016cites this paper
• Effectiveness of medical interventions.

  2015cites this paper
• Optimizing therapy early in multiple sclerosis: An evidence-based view.

  2015cites this paper
• Natalizumab in multiple sclerosis: discontinuation, progressive multifocal leukoencephalopathy and possible use in children

  2015influential citation
• Overview of magnetic resonance imaging for management of relapsing−remitting multiple sclerosis in everyday practice

  2015cites this paper
• Measuring effectiveness.

  2015cites this paper
• Therapieziele und Therapiemanagement bei schubförmigremittierender Multipler Sklerose

  2015cites this paper
• The Effect of Disease Modifying Therapies on Disease Progression in Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-Analysis

  2015cites this paper
• The effects of a pragmatic exercise intervention in people with multiple sclerosis

  2015cites this paper
• Sclerosis Plaques Synthetic MRI in the Detection of Multiple

  year unknowncites this paper